Q32 Bio (QTTB) Cash from Operations Growth (3y) (2020 - 2026)
Q32 Bio (QTTB) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Q32 Bio | 215.94 Mn | 165.19 Mn | - | 20.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.23% |
| Dec 31, 2025 | 38.98% |
| Sep 30, 2025 | 44.64% |
| Jun 30, 2025 | 29.84% |
| Mar 31, 2025 | 25.90% |
| Dec 31, 2024 | 27.85% |
| Sep 30, 2024 | 8.38% |
| Jun 30, 2024 | 2.69% |
| Mar 31, 2024 | 21.27% |
| Dec 31, 2023 | 2.64% |
| Sep 30, 2023 | 36.63% |
| Jun 30, 2023 | 25.94% |
| Mar 31, 2023 | 21.51% |
| Dec 31, 2022 | -1.08% |
| Sep 30, 2022 | 0.73% |
| Jun 30, 2022 | -12.49% |
| Mar 31, 2022 | -19.74% |
| Dec 31, 2021 | -55.59% |
| Sep 30, 2021 | -22.85% |
| Jun 30, 2021 | -35.24% |